Logo image of GRNA

GreenLight Biosciences Holdings PBC (GRNA) Stock Fundamental Analysis

NASDAQ:GRNA - Nasdaq - US39536G1058 - Common Stock - Currency: USD

0.2995  0 (-0.03%)

After market: 0.2995 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to GRNA. GRNA was compared to 571 industry peers in the Biotechnology industry. GRNA has a bad profitability rating. Also its financial health evaluation is rather negative. GRNA is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GRNA has reported negative net income.
In the past year GRNA has reported a negative cash flow from operations.
GRNA Yearly Net Income VS EBIT VS OCF VS FCFGRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

GRNA has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRNA Yearly ROA, ROE, ROICGRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 -2K -4K -6K -8K -10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GRNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRNA Yearly Profit, Operating, Gross MarginsGRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 -2K -4K -6K

More info and screens

2

2. Health

2.1 Basic Checks

GRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GRNA has been increased compared to 1 year ago.
The debt/assets ratio for GRNA has been reduced compared to a year ago.
GRNA Yearly Shares OutstandingGRNA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 50M 100M 150M
GRNA Yearly Total Debt VS Total AssetsGRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M

2.2 Solvency

Based on the Altman-Z score of -9.56, we must say that GRNA is in the distress zone and has some risk of bankruptcy.
GRNA has a worse Altman-Z score (-9.56) than 80.98% of its industry peers.
GRNA has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
GRNA's Debt to Equity ratio of 0.49 is on the low side compared to the rest of the industry. GRNA is outperformed by 76.40% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Altman-Z -9.56
ROIC/WACCN/A
WACC8.59%
GRNA Yearly LT Debt VS Equity VS FCFGRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 50M -50M -100M -150M

2.3 Liquidity

GRNA has a Current Ratio of 1.21. This is a normal value and indicates that GRNA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.21, GRNA is doing worse than 90.15% of the companies in the same industry.
A Quick Ratio of 1.21 indicates that GRNA should not have too much problems paying its short term obligations.
GRNA has a Quick ratio of 1.21. This is amonst the worse of the industry: GRNA underperforms 89.13% of its industry peers.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 1.21
GRNA Yearly Current Assets VS Current LiabilitesGRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

GRNA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.79%.
GRNA shows a strong growth in Revenue. In the last year, the Revenue has grown by 577.34%.
GRNA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.22% yearly.
EPS 1Y (TTM)-5.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.19%
Revenue 1Y (TTM)577.34%
Revenue growth 3Y31.22%
Revenue growth 5YN/A
Sales Q2Q%1386.38%

3.2 Future

GRNA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.95% yearly.
GRNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 157.83% yearly.
EPS Next Y26.28%
EPS Next 2Y12.95%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year167.93%
Revenue Next 2Y157.83%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
GRNA Yearly Revenue VS EstimatesGRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 5M 10M 15M
GRNA Yearly EPS VS EstimatesGRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GRNA. In the last year negative earnings were reported.
Also next year GRNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRNA Price Earnings VS Forward Price EarningsGRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRNA Per share dataGRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as GRNA's earnings are expected to grow with 12.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.95%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GRNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GreenLight Biosciences Holdings PBC

NASDAQ:GRNA (7/21/2023, 8:00:02 PM)

After market: 0.2995 0 (0%)

0.2995

0 (-0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-11 2023-05-11/amc
Earnings (Next)08-14 2023-08-14/amc
Inst Owners0.03%
Inst Owner Change0%
Ins Owners16.91%
Ins Owner Change0%
Market Cap45.43M
Analysts45.71
Price Target0.46 (53.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.16%
Min EPS beat(2)2.16%
Max EPS beat(2)2.16%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)179.87%
Min Revenue beat(2)85.23%
Max Revenue beat(2)274.51%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-80.43%
EPS NQ rev (1m)-58.24%
EPS NQ rev (3m)-7.82%
EPS NY rev (1m)-14.11%
EPS NY rev (3m)-14.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)69.05%
Revenue NY rev (3m)69.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.39
P/FCF N/A
P/OCF N/A
P/B 2.07
P/tB 2.07
EV/EBITDA N/A
EPS(TTM)-1.14
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0.07
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 335.19%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.21
Quick Ratio 1.21
Altman-Z -9.56
F-Score4
WACC8.59%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.19%
EPS Next Y26.28%
EPS Next 2Y12.95%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)577.34%
Revenue growth 3Y31.22%
Revenue growth 5YN/A
Sales Q2Q%1386.38%
Revenue Next Year167.93%
Revenue Next 2Y157.83%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-52.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.89%
OCF growth 3YN/A
OCF growth 5YN/A